Redcare Pharmacy Extends Rally as Analysts Line Up Behind Raised Guidance

Redcare Pharmacy rose 7.4% to EUR 72.90 after Berenberg lifted its target to EUR 102 and Baader kept a Buy, citing raised 2026 guidance.

Shares of Redcare Pharmacy climbed 7.4% on Wednesday to trade at EUR 72.90, giving the online pharmacy group a second straight session of gains as investors returned to the stock following a brief pause. The advance builds on Tuesday's close of EUR 67.85, when the equity finished 2.4% higher. No fresh company announcement accompanied either move, leaving the market to digest a reassessment set in motion by bullish analyst commentary and an upgraded corporate outlook.

That reassessment has now been reinforced from two directions this week. Berenberg lifted its price target on the stock to EUR 102 on Tuesday while keeping a buy rating, a step media reports tied to the revenue forecast management raised in late September. The Baader Bank had already thrown its weight behind the name on Monday, sticking with a "Buy" call and an EUR 85 target. Analyst Volker Bosse used the occasion to mark up his full-year estimates ahead of the upcoming quarterly figures, pointing to an expected above-average performance in the electronic prescription segment.

Guidance Raised Twice, With E-Prescriptions Doing the Heavy Lifting

The analysts' confidence rests squarely on decisions taken by the company itself. On 28 September, Redcare Pharmacy raised its full-year 2026 revenue growth target for the second time, now guiding for 16% to 18% expansion, up from a prior range of 15% to 17%. The driver behind the more optimistic forecast is the momentum in prescription medicines in Germany, where the company now expects 2026 revenue of EUR 730 million to EUR 760 million, compared with an earlier target of EUR 680 million to EUR 720 million.

Preliminary figures for the third quarter suggest that momentum is already visible. German prescription revenue grew 56% year over year during the period, a reading that lends weight to the case both research houses have made for a strong operating quarter.

Chart Picture Improves as Regulatory Tailwind Persists

Technically, the stock is now trading above its 50-day moving average of EUR 62.00, a level that marks a clear recovery from this year's lows even as the shares remain in negative territory on a twelve-month basis. The regulatory framework continues to underpin the digital prescription business, with the e-prescription process allowing customers in Germany to redeem prescriptions through a smartphone app.

Investors will get their first detailed look at how those expectations are translating into hard numbers before the month is out. Redcare Pharmacy has scheduled its third-quarter interim report for 29 October, when management will walk through the period's business development on a conference call.